JPMorgan Chase & Co. assumed coverage on shares of Immunome (NASDAQ:IMNM – Free Report) in a research note published on Tuesday, Marketbeat reports. The firm issued an overweight rating and a $24.00 price objective on the stock. IMNM has been the subject of several other reports. Guggenheim initiated coverage on Immunome in a report on […]
Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) were up 2.7% on Tuesday . The company traded as high as $24.50 and last traded at $24.08. Approximately 59,193 shares traded hands during trading, a decline of 90% from the average daily volume of 570,022 shares. The stock had previously closed at $23.45. Analysts Set […]
Immunome, Inc. (NASDAQ:IMNM – Free Report) – Investment analysts at Wedbush issued their Q1 2024 earnings per share (EPS) estimates for Immunome in a research note issued on Tuesday, February 6th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.24) per share for the quarter. Wedbush currently has a “Outperform” rating […]
By Chris Wack Immunome shares hit their 52-week high of $25.85 on Wednesday, and are now up 381% in the past 12 months. The stock closed Tuesday's session.
By Chris Wack Immunome shares were up 16% to $19.56 after the company agreed to buy AL102 and related drug candidate AL101 from Ayala Pharmaceuticals. Ayala.